Linvesta Emp 25mg/5mg Tablet

Linvesta Emp 25mg/5mg Tablet is a combination medication that contains two active ingredients: EMPAGLIFLOZIN + LINAGLIPTIN It is commonly prescribed for the management of type 2 diabetes mellitus by providing dual-action control over blood glucose levels.

Active Ingredients:

• Empagliflozin (25mg):
  • Empagliflozin belongs to the class of sodium-glucose co-transporter-2 (SGLT2) inhibitors, which work by reducing the reabsorption of glucose by the kidneys, leading to increased glucose excretion in the urine.
• Linagliptin (5mg):
  • Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which enhances the secretion of insulin and helps reduce the production of glucose in the liver.

Used For:

1. Type 2 Diabetes Mellitus: Linvesta Emp is used for the management of type 2 diabetes mellitus to improve blood sugar control.
2. Dual-Action Control: It provides dual-action control over blood glucose levels by reducing glucose reabsorption and increasing insulin secretion.

Dosage and Administration:

• The dosage is typically determined by healthcare providers based on individual response and medical condition.
• Tablets are usually taken orally, with or without food, as directed by the healthcare provider.

Side Effects:

Common side effects may include urinary tract infections, increased urination, and hypoglycemia (low blood sugar). It is important to report any severe or persistent side effects to a healthcare professional.

When Not to Use:

1. Type 1 Diabetes: Linvesta Emp is not indicated for the treatment of type 1 diabetes.
2. Severe Renal Impairment: It is contraindicated in individuals with severe renal impairment or end-stage renal disease.

Precautions and Warnings:

1. Dehydration: Use with caution in individuals at risk of dehydration, such as elderly patients or those taking diuretics.
2. Pancreatitis: Monitor for signs and symptoms of pancreatitis, as it has been reported with DPP-4 inhibitors.

FAQ related to Linvesta Emp 25mg/5mg Tablet:

Q: How does Linvesta Emp 25mg/5mg Tablet help manage type 2 diabetes?

A: Linvesta Emp combines Empagliflozin and Linagliptin, working together to reduce glucose reabsorption by the kidneys and enhance insulin secretion, thereby improving blood sugar control.